IllnessAnophthalmia, microphthalmia: differential diagnosis
Summary
Comprehensive differential diagnostic panel for Anophthalmia/ Microphthalmia comprising 17 or 65 curated genes according to the clinical signs
156,9 kb (Extended panel: incl. additional genes)
- EDTA-anticoagulated blood (3-5 ml)
NGS +
[Sanger]
Gene panel
Selected genes
Name | Exon Length (bp) | OMIM-G | Referenz-Seq. | Heredity |
---|---|---|---|---|
ALDH1A3 | 1539 | NM_000693.4 | AR | |
BCOR | 5166 | NM_017745.6 | XL | |
BMP4 | 1227 | NM_001202.6 | AD | |
FOXE3 | 960 | NM_012186.3 | AR | |
GDF3 | 1095 | NM_020634.3 | AD | |
GDF6 | 1368 | NM_001001557.4 | AD | |
HCCS | 807 | NM_005333.5 | XL | |
MFRP | 1740 | NM_031433.4 | AR | |
OTX2 | 870 | NM_172337.3 | AD | |
PAX6 | 1269 | NM_000280.5 | AD | |
RAX | 1041 | NM_013435.3 | AR | |
SHH | 1389 | NM_000193.4 | AD | |
SIX6 | 741 | NM_007374.3 | AR | |
SMOC1 | 1308 | NM_001034852.3 | AR | |
SOX2 | 954 | NM_003106.4 | AD | |
STRA6 | 2004 | NM_001142617.2 | AR | |
VSX2 | 1086 | NM_182894.3 | AR | |
ABCB6 | 2529 | NM_005689.4 | AD | |
ATOH7 | 459 | NM_145178.4 | AR | |
BMP7 | 1296 | NM_001719.3 | AD | |
C12orf57 | 381 | NM_138425.4 | AR | |
CHD7 | 8994 | NM_017780.4 | AD | |
COL4A1 | 5010 | NM_001845.6 | AD, Mult | |
CRYBA4 | 591 | NM_001886.3 | AD | |
FAT1 | 13767 | NM_005245.4 | AR | |
FOXC1 | 1662 | NM_001453.3 | AD | |
FRAS1 | 12039 | NM_025074.7 | AR | |
FREM1 | 6540 | NM_144966.7 | AR | |
FREM2 | 9510 | NM_207361.6 | AR | |
GRIP1 | 3231 | NM_021150.4 | AR | |
HESX1 | 558 | NM_003865.3 | AD, AR | |
HMGB3 | 603 | NM_005342.4 | XL | |
KMT2D | 16614 | NM_003482.4 | AD | |
MAB21L2 | 1080 | NM_006439.5 | AD, AR | |
MYRF | 3506 | NM_001127392.3 | AD | |
NAA10 | 663 | NM_001256119.2 | XL | |
NHS | 4425 | NM_001136024.4 | XL | |
PAX2 | 1254 | NM_003987.5 | AD | |
PITX2 | 816 | NM_153427.2 | AD | |
PORCN | 1386 | NM_203475.3 | XL | |
PQBP1 | 798 | NM_005710.2 | XLR | |
PRSS56 | 1812 | NM_001195129.2 | AR | |
PXDN | 4440 | NM_012293.3 | AR | |
RAB18 | 621 | NM_021252.5 | AR | |
RAB3GAP1 | 2946 | NM_012233.3 | AR | |
RAB3GAP2 | 4182 | NM_012414.4 | AR | |
RARB | 1347 | NM_000965.5 | AD, AR | |
SALL2 | 3024 | NM_005407.3 | AR | |
SMO | 2364 | NM_005631.5 | AD | |
TBC1D20 | 1212 | NM_144628.4 | AR | |
TENM3 | 8100 | NM_001080477.4 | AR | |
TFAP2A | 1296 | NM_001032280.3 | AD | |
TMEM98 | 681 | NM_001033504.2 | AD | |
VAX1 | 1005 | NM_001112704.2 | AR | |
YAP1 | 1515 | NM_001130145.3 | AD |
Informations about the disease
In microphthalmia/anophthalmia, one or both eyeballs are particularly small or missing completely. Microphthalmia may or may not result in significant vision loss. The patients may have unilateral or bilateral colobomas that also impair vision. Affected individuals have sometimes other ocular abnormalities, including cataracts, narrowed palpebral fissures and microcornea. In 30-50% of the affected, microphthalmia is syndromic. The disorder can be caused by alterations in many genes involved in early eye development, most of which have not yet been identified. Many genetic alterations associated with isolated microphthalmia have been identified only in very few patients. In addition, microphthalmia can also be caused by environmental factors, such as deficiency of certain vitamins during pregnancy, radiation, infections or by exposure to teratogens. Isolated microphthalmia is sometimes inherited in an autosomal recessive manner, sometimes with decreased penetrance. In syndromal cases, microphthalmia may be clustered according to the inheritance pattern for this condition. Often microphthalmia is not inherited, only one affected person exists per family. Therefore, a negative molecular genetic result does not exclude the clinical diagnosis.
Exemplary references: https://www.ncbi.nlm.nih.gov/books/NBK1300/
https://www.ncbi.nlm.nih.gov/books/NBK7041/
https://www.ncbi.nlm.nih.gov/books/NBK1728/
- Alias: Anophthalmia-microphthalmia syndrome
- Alias: Anophthalmos, microphthalmos
- Alias: Microphthalmia-anophthalmia-coloboma
- Allelic: Aniridia (PAX6)
- Allelic: Aortic aneurysm, familial thoracic 11, susceptibility to (FOXE3)
- Allelic: Basal cell nevus syndrome (PTCH1)
- Allelic: Bifid nose with/-out anorectal + renal anomalies (FREM1)
- Allelic: CHARGE [Coloboma, Heart anom., choanal Atresia, Retard., Genital/Ear anom.] syndrome (CHD7)
- Allelic: Cardiac-urogenital syndrome (MYRF)
- Allelic: Cataract 34, multiple type (FOXE3)
- Allelic: Cataract 40, XL (NHS)
- Allelic: Cataract with late-onset corneal dystrophy (PAX6)
- Allelic: Coloboma of optic nerve (PAX6)
- Allelic: Coloboma, ocular (PAX6)
- Allelic: Encephalitis/encephalopathy, mild, reversible myelin vacuolization (MYRF)
- Allelic: Facioscapulohumeral muscular dystrophy 2, digenic (SMCHD1)
- Allelic: Foveal hypoplasia 1 (PAX6)
- Allelic: Glomerulosclerosis, focal segmental, 7 (PAX2)
- Allelic: Growth hormone deficiency with pituitary anomalies (HESX1)
- Allelic: Holoprosencephaly 3 (SHH)
- Allelic: Hypogonadotropic hypogonadism 5 with/-out anosmia (CHD7)
- Allelic: Keratitis (PAX6)
- Allelic: Klippel-Feil syndrome 1, AD (GDF6)
- Allelic: Klippel-Feil syndrome 3, AD (GDF3)
- Allelic: Leber congenital amaurosis 17 (GDF6)
- Allelic: Linear skin defects with multiple congenital anomalies 1 (HCCS)
- Allelic: Morning glory disc anomaly (PAX6)
- Allelic: Multiple synostoses syndrome 4 (GDF6)
- Allelic: Nance-Horan [cataract-dental] syndrome (NHS)
- Allelic: Ogden syndrome [growth failure, delayed psychomotor development, dysmorphisms] (NAA10)
- Allelic: Optic disc anomalies with retinal and/or macular dystrophy (SIX6)
- Allelic: Optic nerve hypoplasia (PAX6)
- Allelic: Pallister-Hall-like syndrome (SMO)
- Allelic: Persistent hyperplastic primary vitreous, AR (ATOH7)
- Allelic: Pituitary hormone deficiency, combined, 5 (HESX1)
- Allelic: Pituitary hormone deficiency, combined, 6 (OTX2)
- Allelic: Retinal dystrophy, early-onset, with/-out pituitary dysfunction (OTX2)
- Allelic: Ring dermoid of cornea (PITX2)
- Allelic: Schizencephaly (SHH)
- Allelic: Single median maxillary central incisor (SHH)
- Allelic: Temtamy syndrome [Ment. retard., craniofacial dysmorph., coloboma] (C13orf57)
- Allelic: Trigonocephaly 2 (FREM1)
- Anophthalmia (PAX6)
- Anophthalmia, microphthalmia (RAX, SIX6)
- Anterior segment dysgenesis 2, multiple subtypes (FOXE3)
- Anterior segment dysgenesis 3, multiple subtypes (FOXC1)
- Anterior segment dysgenesis 4 (PITX2)
- Anterior segment dysgenesis 5, multiple subtypes (PAX6)
- Anterior segment dysgenesis 7, with sclerocornea (PXDN)
- Axenfeld-Rieger syndrome, type 1 (PITX2)
- Axenfeld-Rieger syndrome, type 3 (FOXC1)
- BMP4-Related Syndromic Microphthalmia (BMP4)
- Bilateral microphthalmia, short stature + facial dysmorphism [panelapp] (OLFM2)
- Bosma arhinia microphthalmia syndrome (SMCHD1)
- Branchiooculofacial syndrome (TFAP2A)
- Cataract 9, multiple types (CRYAA)
- Cerebrooculofacioskeletal syndrome 4 (ERCC1)
- Coloboma, ocular, AR (SALL2)
- Coloboma, ocular, with/-out hearing impairment, cleft lip/palate, mental retardation (YAP1)
- Colobomatous microphthalmia [panelapp] (FAT1)
- Curry-Jones syndrome, somatic mosaic (SMO)
- Focal dermal hypoplasia (PORCN)
- Fraser syndrome 3 [cryptophthalmus + other malformations] (GRIP1)
- Fraser syndrome [cryptophthalmus + other malformations] (FRAS1)
- Holoprosencephaly 7 (PTCH1)
- Isolated Microphthalmia (MFRP)
- Joubert syndrome 22 (PDE6D)
- Kabuki syndrome 1 (KMT2D)
- Manitoba oculotrichoanal syndrome (FREM1)
- Martsolf [cataract-mental retardation-hypogonadism] syndrome (RAB3GAP2)
- Microphthalmia with cataract 2 (SIX6)
- Microphthalmia with coloboma 3 (VSX2)
- Microphthalmia with coloboma 5 (SHH)
- Microphthalmia with coloboma 6 (GDF3)
- Microphthalmia with coloboma 6, digenic (GDF6)
- Microphthalmia with limb anomalies (SMOC1)
- Microphthalmia, Kabuki syndrome 1 (KMT2D)
- Microphthalmia, coloboma, micrognathia, diaphragmatic hernia [panelapp] (TMX3)
- Microphthalmia, isolated 2 (VSX2)
- Microphthalmia, isolated 3 (RAX)
- Microphthalmia, isolated 4 (GDF6)
- Microphthalmia, isolated 5 (MFRP)
- Microphthalmia, isolated 6 (PRSS56)
- Microphthalmia, isolated 7 (GDF3)
- Microphthalmia, isolated 8 (ALDH1A3)
- Microphthalmia, isolated, with coloboma 7 (ABCB6)
- Microphthalmia, isolated, with coloboma 8 (STRA6)
- Microphthalmia, isolated, with coloboma 9 (TENM3)
- Microphthalmia, syndromic 1 (NAA10)
- Microphthalmia, syndromic 11 (VAX1)
- Microphthalmia, syndromic 13 (HMGB3)
- Microphthalmia, syndromic 14 (MAB21L2)
- Microphthalmia, syndromic 15 (TENM3)
- Microphthalmia, syndromic 2 (BCOR)
- Microphthalmia, syndromic 3 (SOX2)
- Microphthalmia, syndromic 5 (OTX2)
- Microphthalmia, syndromic 6 (BMP4)
- Microphthalmia, syndromic 7 (HCCS)
- Microphthalmia, syndromic 9 (STRA6)
- Microphthalmia/coloboma + skeletal dysplasia syndrome (MAB21L2)
- Nanophthalmos 2 (NFRP)
- Nanophthalmos 4 (TMEM98)
- Nanophthalmos [panelapp] (MYRF)
- Nanophthalmos, high hyperopia (MYRF)
- OTX2-related syndromic microphthalmia 4 (OTX2)
- Oculogastrointestinal neurodevelopmental syndrome (CAPN15)
- Optic nerve hypoplasia and abnormalities of the central nervous system (SOX2)
- Orofaciodigital syndrome IX [panelapp] (SCLT1)
- Papillorenal [renal coloboma] syndrome (PAX2)
- Renpenning [mental retardation, XL syndromic] syndrome (PQBP1)
- Septooptic dysplasia [optic nerve hypopl., pituitary hypoplasia, midline brain anomalies] (HESX1)
- Warburg micro syndrome 1 (RAB3GAP1)
- Warburg micro syndrome 12 (RARB)
- Warburg micro syndrome 2 (RAB3GAP2)
- Warburg micro syndrome 3 (RAB18)
- Warburg micro syndrome 4 (TBC1D20)
- AD
- AR
- Mult
- XL
- XLR
- Multiple OMIM-Ps
Bioinformatics and clinical interpretation
Test-Stärken
- DAkkS-akkreditiertes Labor
- EU-Richtlinie für IVD in Umsetzung
- Qualitäts-kontrolliert arbeitendes Personal
- Leistungsstarke Sequenzierungstechnologien, fortschrittliche Target-Anreicherungsmethoden und Präzisions-Bioinformatik-Pipelines sorgen für überragende analytische Leistung
- Sorgfältige Kuratierung klinisch relevanter und wissenschaftlich begründeter Gen-Panels
- eine Vielzahl nicht Protein-kodierender Varianten, die in unseren klinischen NGS-Tests mit erfasst werden
- unser strenges Variantenklassifizierungsschema nach ACMG-Kriterien
- unser systematischer klinischer Interpretations-Workflow mit proprietärer Software ermöglicht die genaue und nachvollziehbare Verarbeitung von NGS-Daten
- unsere umfassenden klinischen Aussagen
Testeinschränkungen
- Gene mit eingeschränkter Abdeckung werden gekennzeichnet
- Gene mit kompletten oder partiellen Duplikationen werden gekennzeichnet
- es wird angenommen, dass ein Gen suboptimal abgedeckt ist, wenn >90% der Nukleotide des Gens bei einem Mapping-Qualitätsfaktor von >20 (MQ>20) nicht abgedeckt sind
- die Sensitivität der Diagnostik zur Erkennung von Varianten mit genannten Testeinschränkungen ist möglicherweise begrenzt bei:
- Gen-Konversionen
- komplexe Inversionen
- Balancierte Translokationen
- Mitochondriale Varianten
- Repeat-Expansionen, sofern nicht anders dokumentiert
- nicht kodierende Varianten, die Krankheiten verursachen, die von diesem Panel nicht mit abgedeckt werden
- niedriger Mosaik-Status
- Repeat-Blöcke von Mononukleotiden
- Indels >50bp (Insertionen-Deletionen)
- Deletionen oder Duplikationen einzelner Exons
- Varianten innerhalb von Pseudogenen
- die analytische Sensitivität kann geringer ausfallen werden, wenn die DNA nicht von amedes genetics extrahiert wurde
Laboratory requirement
Die in grün gezeigten Gene sind kuratiert und werden als Gen-Panel untersucht. Eine Erweiterung des Panels (blau gezeigte Gene, jeweils ebenfalls kuratiert) kann auf Anfrage erfolgen. Sofern unter "Erweitertes Panel" ein Minuszeichen angezeigt wird, sind nur Core-/Basis-Gene verfügbar.
Für die Anforderung einer genetischen Untersuchung senden Sie uns bitte die Krankheits-ID auf einem Überweisungsschein. Bitte die Material-Angabe beachten.
Für privat versicherte Patienten empfehlen wir einen Antrag auf Kostenübernahme bei der Krankenversicherung.
Die Untersuchung wird auch für Selbstzahler angeboten.